Genentech Oncology
There were ~1.6 million new cases of gastroesophageal cancers across the globe in 2018. This represents the seventh (esophageal) and fifth (stomach) most common cancers worldwide1
The frequency of overexpression of HER2 is slightly greater for cancers at the gastroesophageal junction in comparison to the stomach, and overexpression in the stomach varies by2:
Histologic type (more common in intestinal type than in diffuse type)2
Differentiation (more common in well and moderately differentiated tumors than in poorly differentiated tumors)2
Guideline-recommended sample preparation helps to improve test accuracy2
The HER2 oncogene is amplified and/or overexpressed in 7% to 38% of gastroesophageal adenocarcinoma cases2
Image adapted from Bartley AN, et al. Arch Pathol Lab Med. 2016;140(12):1345-1363.
In comparison with breast cancer, the heterogeneity of immunostaining is greater in gastroesophageal adenocarcinoma2
Gastroesophageal adenocarcinoma cells do not often present with the completeness of membrane staining that is required for positivity in breast cancer2
HER2 expression is often seen in a basolateral pattern in gastroesophageal adenocarcinoma2
The CAP/ASCP/ASCO guidelines and NCCN recommend the use of the Ruschoff/Hofmann method in scoring HER2 IHC and ISH results for gastroesophageal adenocarcinoma2,4
If IHC is used as a primary test platform, applying breast cancer principles and scoring criteria to gastroesophageal adenocarcinoma may result in a 50% false-negative rate3
Breast cancer images provided by Leo A Niemeier, MD. Advanced GEA biopsy images provided by David G Hicks, MD, Bruce Horten, MD, and Christa Whitney-Miller, MD.
The guidelines for scoring ISH differ from those used for breast cancer to compensate for the greater heterogeneity of GEA2
ASCO=American Society of Clinical Oncology; ASCP=American Society for Clinical Pathology; CAP=College of American Pathologists; CEP17=chromosome enumeration probe 17; GEA=gastroesophageal carcinoma; HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; NCCN=National Comprehensive Cancer Network
Worldwide cancer data. World Cancer Research Fund International. https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. Accessed January 28, 2020.
Worldwide cancer data. World Cancer Research Fund International. https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. Accessed January 28, 2020.
Bartley AN, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma. Arch Pathol Lab Med. 2016;140(12):1345-1363. PMID: 27841667
Bartley AN, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma. Arch Pathol Lab Med. 2016;140(12):1345-1363. PMID: 27841667
Rüschoff J, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307. PMID: 20665045
Rüschoff J, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307. PMID: 20665045
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 31, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 31, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Genentech. Data on File. 2019.
Genentech. Data on File. 2019.
Learn more about the importance of oncologic biomarkers and what they can tell you.
Learn more about how cancer avoids immune response.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.